FDA Approves Amuttra (Vutrisiran) for Rare Pediatric Disease Priority Review Voucher Redemption
April 19, 2025
April 19, 2025
WASHINGTON, April 19 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) has announced the approval of AMVUTTRA (vutrisiran) for a rare pediatric disease priority review voucher.
The approval, issued on March 20, 2025, follows the successful submission of a supplemental application (Supplement-06) by the drug's manufacturer. AMVUTTRA is now recognized for meeting the criteria required to redeem the priority review voucher, which is gr . . .
The approval, issued on March 20, 2025, follows the successful submission of a supplemental application (Supplement-06) by the drug's manufacturer. AMVUTTRA is now recognized for meeting the criteria required to redeem the priority review voucher, which is gr . . .